Thermogenic effects of sibutramine and its metabolites.
1. The thermogenic activity of the serotonin and noradrenaline reuptake inhibitor sibutramine (BTS 54524; Reductil) was investigated by measuring oxygen consumption (VO2) in rats treated with sibutramine or its two pharmacologically-active metabolites. 2. Sibutramine caused a dose-dependent rise in VO2, with a dose of 10 mg kg(-1) of sibutramine or its metabolites producing increases of up to 30% that were sustained for at least 6 h, and accompanied by significant increases (0.5-1.0 degrees C) in body temperature. 3. Based on the accumulation in vivo of radiolabelled 2-deoxy-[3H]-glucose, sibutramine had little or no effect on glucose utilization in most tissues, but caused an 18 fold increase in brown adipose tissue (BAT). 4. Combined high, non-selective doses (20 mg kg(-1)) of the beta-adrenoceptor antagonists, atenolol and ICI 118551, inhibited completely the VO2 response to sibutramine, but the response was unaffected by low, beta1-adrenoceptor-selective (atenolol) or beta2-adrenoceptor-selective (ICI 118551) doses (1 mg kg(-1)). 5. The ganglionic blocking agent, chlorisondamine (15 mg kg(-1)), inhibited completely the VO2 response to the metabolites of sibutramine, but had no effect on the thermogenic response to the beta3-adrenoceptor-selective agonist BRL 35135. 6. Similar thermogenic responses were produced by simultaneous injection of nisoxetine and fluoxetine at doses (30 mg kg(-1)) that had no effect on VO2 when injected individually. 7. It is concluded that stimulation of thermogenesis by sibutramine requires central reuptake inhibition of both serotonin and noradrenaline, resulting in increased efferent sympathetic activation of BAT thermogenesis via beta3-adrenoceptor, and that this contributes to the compound's activity as an anti-obesity agent.
Connoley
I P
IP
Department of Physiology, St George's Hospital Medical School, University of London, Tooting.
Liu
Y L
YL
Frost
I
I
Reckless
I P
IP
Heal
D J
DJ
Stock
M J
MJ
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D001067:Appetite Depressants / Q000378:metabolism / Q000494:pharmacology*; D001262:Atenolol / Q000494:pharmacology; D001831:Body Temperature / Q000187:drug effects; D001833:Body Temperature Regulation / Q000187:drug effects*; D002714:Chlorisondamine / Q000494:pharmacology; D003503:Cyclobutanes / Q000378:metabolism / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005473:Fluoxetine / Q000031:analogs & derivatives / Q000494:pharmacology; D005730:Ganglionic Blockers / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D010627:Phenethylamines / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D018687:Antidepressive Agents, Second-Generation; D001067:Appetite Depressants; D003503:Cyclobutanes; D005730:Ganglionic Blockers; D010627:Phenethylamines; D011412:Propanolamines; D005473:Fluoxetine; C011386:nisoxetine; C026777:ICI 118551; D001262:Atenolol; C063157:BRL 35135; D005947:Glucose; D002714:Chlorisondamine; C058254:sibutramine